| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/15/2009 | WO2008135661A3 Use of citrulline for the treatment of conditions linked to an increase in protein carbonylation |
| 01/15/2009 | WO2008133952A3 Transmucosal treatment with fentanyl in patients with mucositis |
| 01/15/2009 | WO2008112483A3 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof |
| 01/15/2009 | WO2008110699A3 Azabicycloalkane derivatives, preparation thereof and use thereof in therapy |
| 01/15/2009 | WO2008097546A3 Compounds that inhibit cholinesterase |
| 01/15/2009 | US20090018218 METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS |
| 01/15/2009 | US20090018208 Novel Succinate Salt of O-Desmethyl-Venlafaxine |
| 01/15/2009 | US20090018205 Methods for treatment of migraine and symptoms thereof |
| 01/15/2009 | US20090018203 Modified release compositions of milnacipran |
| 01/15/2009 | US20090018202 Modafinil compositions |
| 01/15/2009 | US20090018198 Method for treating a motoneuron disorder |
| 01/15/2009 | US20090018197 Methods for treating status epilepticus and related conditions |
| 01/15/2009 | US20090018191 Deuterated Catecholamine Derivatives and Medicaments Comprising Said Compounds |
| 01/15/2009 | US20090018185 Compositions and products containing s-equol, and methods for their making |
| 01/15/2009 | US20090018183 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands |
| 01/15/2009 | US20090018167 angiogenesis inhibitors such as 1-phenyl-3-pyridin-2-ylprop-2-en-1-one, having antitumor and anticarcinogenic activity; treatment of skin disorders such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, and lymphangiogenesis, as well as chronic inflammatory disease such as arthritis |
| 01/15/2009 | US20090018163 Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| 01/15/2009 | US20090018160 Heterocyclic Compounds with Affinity to Muscarinic Receptors |
| 01/15/2009 | US20090018148 Xanthine Derivatives, Processes For Preparing Them And Their Uses |
| 01/15/2009 | US20090018147 Compounds for modulating TRPV3 function |
| 01/15/2009 | US20090018143 Thio-substituted arylmethanesulfinyl derivatives |
| 01/15/2009 | US20090018137 Buffer intracellular reduction and oxidation for the stressed cells in various disease states; beneficial as adjunctive support therapy, multiple chemical sensitivity syndrome, Charcot-Marie-Tooth disease, Dejerine-Sottas syndrome, Roussy-Levy syndrome, Rosenberg Chutorian syndrome, Korsakoff syndrome |
| 01/15/2009 | US20090018133 Novel Adamantane Derivatives |
| 01/15/2009 | US20090018132 Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| 01/15/2009 | US20090018131 Quinazoline derivatives as p13 kinase inhibitors |
| 01/15/2009 | US20090018124 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same |
| 01/15/2009 | US20090018120 Amidine derivatives and their applications as a medicament |
| 01/15/2009 | US20090018119 Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 01/15/2009 | US20090018114 Novel compounds as cannabinoid receptor ligands |
| 01/15/2009 | US20090018112 Compounds and Uses Thereof |
| 01/15/2009 | US20090018103 Diaminoalkane Aspartic Protease Inhibitors |
| 01/15/2009 | US20090018094 Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
| 01/15/2009 | US20090018087 Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism |
| 01/15/2009 | US20090018084 Methods of restoring cognitive ability using non-peptidic compounds |
| 01/15/2009 | US20090018077 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018076 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018073 Administering polypeptide of growth factor to increase mitogenesis; bind to receptors and increase cell differentiation and survival |
| 01/15/2009 | US20090018068 G-protein coupled receptors |
| 01/15/2009 | US20090018060 Thymus-specific protein |
| 01/15/2009 | US20090017534 Nucleotide sequences coding voltage-gated transport proteins for use as screening tools to identify modulators for treatment and prevention of nervous, muscular, glandular, immune, reproductive and epithelial tissue disorders |
| 01/15/2009 | US20090017494 Tick octopamine receptor nucleic acid molecules, proteins and uses thereof |
| 01/15/2009 | US20090017143 Composition for treatment of alcoholism |
| 01/15/2009 | US20090017121 dispersed in a polymerc matrix comprising swellable hydrophilic polyethylene oxide that swells unrestrained dimensionally by imbibing H2O to increase its size to promote gastric retention of the dosage form in a stomach in fed mode, upon contact with H2O gabapentin released by diffusion; bioavailability |
| 01/15/2009 | US20090017113 Duloxetine formulations |
| 01/15/2009 | US20090017112 Compounds for Inhibiting Beta-Amyloid Production |
| 01/15/2009 | US20090017102 Enhancing transdermal delivery of opiod antagonists and agonistis using codrugs links to bupropion or hydroxybupropion |
| 01/15/2009 | US20090017047 Preparation for the Prevention and Treatment of Stress Conditions as Well as Functional and Organic Disorders of the Nervous System and Metabolic Disorders |
| 01/15/2009 | US20090017040 Monoclonal antibody |
| 01/15/2009 | US20090017039 SP35 Antibodies and uses thereof |
| 01/15/2009 | US20090017032 Mammalian cx3c chemokine antibodies |
| 01/15/2009 | US20090017015 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| 01/15/2009 | US20090017014 Compositions and methods for the treatment of immune related diseases |
| 01/15/2009 | US20090017005 Delivery of Therapeutic Compounds to the Brain and Other Tissues |
| 01/15/2009 | US20090017003 Thiosulfonate anti-inflammatory agents |
| 01/15/2009 | US20090017002 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
| 01/15/2009 | US20090016995 Method of Treating Cognitive Decline and Synaptic Loss Related to Alzheimer's Disease |
| 01/15/2009 | US20090016963 Genes involved in neurodegenerative conditions |
| 01/15/2009 | US20090016959 Drug delivery across the blood-brain barrier using polypeptides; neurological diseases; aprotinin |
| 01/15/2009 | DE102007030495A1 Use of creatine containing preparation e.g. for improving memory, retentivity, long-term memory and for preventing mental fatigue condition, comprising e.g. Ginkgo biloba, ginseng and niacin |
| 01/15/2009 | CA2707344A1 Stable salts of s-adenosylmethionine and process for the preparation thereof |
| 01/15/2009 | CA2693742A1 Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| 01/15/2009 | CA2693697A1 Treatment of progressive neurodegenerative disease with ibudilast |
| 01/15/2009 | CA2692801A1 Methods of inhibiting the formation of amyloid-.beta. diffusable ligands using acylhydrazide compounds |
| 01/15/2009 | CA2692783A1 Quinazolinone t-type calcium channel antagonists |
| 01/15/2009 | CA2692775A1 Methods of enhancing cognitive function using non-peptidic compounds |
| 01/15/2009 | CA2692773A1 Methods of modifying amyloid .beta. oligomers using non-peptidic compounds |
| 01/15/2009 | CA2692608A1 Amino acid derivatives |
| 01/15/2009 | CA2692539A1 New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin |
| 01/15/2009 | CA2692485A1 Compounds and methods for modulating rho gtpases |
| 01/15/2009 | CA2691542A1 Tetrahydropyranochromene gamma secretase inhibitors |
| 01/15/2009 | CA2690719A1 Treatment of neuropathic pain |
| 01/15/2009 | CA2687750A1 Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture |
| 01/14/2009 | EP2014764A1 Method of producing dry yeast containing s-adenosyl-l-methionine and composition for oral intake |
| 01/14/2009 | EP2014677A1 A-33 related antigens and their pharmacological uses |
| 01/14/2009 | EP2014651A1 Compounds and methods for modulating Rho GTPases |
| 01/14/2009 | EP2014297A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 01/14/2009 | EP2014293A1 Use of argon in gaseous state to treat neurointoxication |
| 01/14/2009 | EP2014288A1 Combination of benzyl-4, 5-dihydro-1H-imidazole derivative and an opioid receptor ligand |
| 01/14/2009 | EP2014282A2 Treatment of depression |
| 01/14/2009 | EP2014178A1 Temporally meal menu for infants |
| 01/14/2009 | EP2013216A2 Novel spiro [imidazolidine-4, 3' -indole] 2, 2', 5' (1h) triones for treatment of conditions associated with vanilloid receptor 1 |
| 01/14/2009 | EP2013215A2 Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-triones for treatment of conditions associated with vanilloid receptor 1 |
| 01/14/2009 | EP2013214A2 Constrained compounds as cgrp-receptor antagonists |
| 01/14/2009 | EP2013213A2 Constrained compounds as cgrp-receptor antagonists |
| 01/14/2009 | EP2013209A2 Pyrazolo-tetrahydropyridine derivatives as orexin receptor antagonists |
| 01/14/2009 | EP2013182A2 Aminoquinolones as gsk-3 inhibitors |
| 01/14/2009 | EP2013181A1 Pyridyl compounds |
| 01/14/2009 | EP2013179A1 Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 01/14/2009 | EP2013166A2 N-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use |
| 01/14/2009 | EP2013165A1 Diphenylazetidinone derivates possessing cholesterol absor tion inhibitor activit. |
| 01/14/2009 | EP2012819A2 Stimulation of neuron regeneration by secretory leukocyte protease inhibitor |
| 01/14/2009 | EP2012785A1 Mono and combination therapy with a m1/m4 muscarinic agonist (sabcomeline) for treatment of cognitive disorders in schizophrenia |
| 01/14/2009 | EP2012784A1 Mono and combination therapy of m1/m4 agonist (sabcomeline) for treatment of negative symptoms of schizophrenia |
| 01/14/2009 | EP2012783A1 Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome |
| 01/14/2009 | EP2012782A1 USE OF IMIDAZO[2,1-b)]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN |
| 01/14/2009 | EP2012775A1 Use of cbx cannabinoid receptor modulators as potassium channel modulators |
| 01/14/2009 | EP2012774A1 Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| 01/14/2009 | EP2012769A1 Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms |
| 01/14/2009 | EP2012762A2 Intranasal administration of ketamine to treat depression |
| 01/14/2009 | EP2012760A2 Purine derivatives for use as adenosin a2a receptor agonists |